Unpacking the OPPS proposed rule’s redistribution effects

The CY 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) proposed rule is not just another routine annual rate update; it reflects CMS’s continuing effort to realign Medicare outpatient reimbursement and advance broader policy objectives through payment reform.

CMS once again proposes significant changes to 340B drug reimbursement, seeks to expand site-neutral payment policies for certain off-campus hospital services and introduces enhanced compliance requirements for provider-based departments (PBDs). Taken together, the major policy proposals focus CMS’s efforts on reducing reimbursement differences across care settings and on the basis of 340B participation status. For hospitals with substantial 340B participation or significant off-campus outpatient operations, these proposals may have a greater financial impact than the headline 2.4 percent OPPS payment update because they change where outpatient dollars go, not simply how much CMS pays overall.

340B: CMS tries again, with survey data

CMS previously sought to reduce payment levels for 340B acquired drugs in the hospital outpatient setting to average sales price (ASP) minus 22.5 percent in 2018 and 2019. Those policies were subsequently challenged and overturned by the US Supreme Court in American Hospital Association v. Becerra on the rationale that CMS’s failure to conduct a cost acquisition survey required 340B-acquired drugs to be reimbursed at ASP plus 6 percent under the statutory ASP methodology.

This year’s proposal will reinstate the previous policy following CMS’s performance of a drug acquisition cost survey that the Court found lacking in AHA v. Becerra. The survey was conducted between January 1, 2026, and April 7, 2026, at the direction of the White House, pursuant to Executive Order 14273, entitled “Lowering Drug Prices by Once Again Putting Americans First.”

CMS now contends that its OPPS Drug Acquisition Cost Survey provides the statutory basis to depart from the default ASP plus 6 percent methodology for 340B-acquired drugs. In Section C of the proposed rule, CMS states that although approximately 43.6 percent of survey-eligible hospitals submitted responses, only 29.8 percent reported acquisition cost data. CMS also notes that some hospitals responded only to say that they would not provide acquisition data, including through what CMS describes as “coordinated form letters.” On that basis, CMS proposes to reimburse 340B-acquired drugs at ASP minus 33.4 percent – an even larger rate decrease than the prior 2018 and 2019 rates that the Supreme Court overturned. CMS states that its survey found significant differences between acquisition costs for drugs purchased through the 340B program and those acquired outside the program.

CMS estimates that the proposal would reduce Medicare Part B drug payments by approximately US$4.55 billion and beneficiary cost-sharing obligations by approximately US$1.15 billion in the first year. Because the OPPS is required to operate in a budget-neutral manner, those savings would be redistributed through higher payments for non-drug outpatient services.

Separately, CMS is proposing to accelerate the recovery of approximately US$7.8 billion in additional non-drug OPPS payments that hospitals received between 2018 and 2022 as a result of the agency's prior 340B payment policy. In its November 2023 remedy rule, CMS adopted a prospective offset that reduced the OPPS conversion factor for non-drug services by 0.5 percent beginning in CY 2026. CMS now proposes to increase that offset to 3 percent beginning in CY 2027, estimating that the larger reduction will allow the agency to recover the full US$7.8 billion by CY 2029.

Taken together, these proposals would significantly reallocate OPPS payments. If finalized, hospitals with substantial 340B drug utilization would face lower reimbursement for 340B-acquired drugs, while the budget-neutral redistribution of those savings would increase payments for non-drug services. At the same time, hospitals subject to the separate 340B remedy offset would face larger reductions in non-drug OPPS payments as CMS accelerates recovery of the earlier budget-neutrality adjustment. As a result, the financial impact is likely to be widespread and vary considerably across providers.

CMS proposes to continue exempting rural sole community hospitals, children's hospitals and PPS-exempt cancer hospitals from the reduced 340B drug payment rate, while outpatient reimbursement for critical access hospitals remains outside the OPPS. CMS also proposes expanded modifier requirements to distinguish 340B-acquired drugs subject to the reduced payment rate, exempt 340B drugs and separately payable non-340B drugs. As a practical matter, hospitals may need to make significant adjustments to pharmacy, billing and revenue cycle operations if this policy is finalized.

The proposal is nevertheless likely to face enhanced scrutiny. The agency's position is arguably stronger than it was in 2022 because it now relies on acquisition cost survey data. However, any future challenge is likely to focus less on the statutory deficiency identified by the Supreme Court and more on the survey itself, including its design, representativeness and whether it provides an adequate basis for the payment reduction. For hospitals considering comments, the strength of the administrative record may matter almost as much as the substance of the payment cut itself.

Imaging: The next site-neutral step

CMS continued its efforts to propose site-neutral payment policies between hospital outpatient departments and physician office settings by proposing site-neutral payment for imaging services that do not use contrast when performed in excepted off-campus provider-based departments (PBDs). The agency previously finalized site-neutral payments for clinic visits in 2019 and drug administration services in 2026. Specifically, CMS proposes Ambulatory Payment Classifications (APCs) 5521 through 5524 and composite APCs 8004, 8005 and 8007 will be paid at a Physician Fee Schedule (PFS) equivalent payment rate when those services are furnished in excepted off-campus PBDs. Non-excepted off-campus PBDs are already subject to payment adjustments intended to promote payment parity between non-excepted off-campus PBDs and physician offices pursuant to Section 603 of the Bipartisan Budget Act of 2015. Rural sole community hospitals would be exempted from the proposal. CMS estimates this policy would reduce Medicare Part B expenditures by approximately US$260 million in the first year, including approximately US$190 million in program savings, approximately US$70 million in reduced beneficiary premiums and approximately US$70 million in lower beneficiary cost-sharing obligations.

What makes this proposal notable is not simply the addition of a new group of APCs. Unlike the proposed 340B drug payment reduction, which must be implemented in a budget-neutral manner, the imaging policy would produce direct savings because CMS is using its authority to control “unnecessary” increases in the volume of outpatient department services. As a result, affected off-campus departments would experience a direct reduction in reimbursement rather than a redistribution of OPPS payments.

The proposal stops short of applying site-neutral payment to on-campus departments, but it continues a pattern established by CMS in recent years. As discussed above, the agency first applied a PFS-equivalent rate to clinic visits furnished in excepted off-campus PBDs and later expanded the policy to include drug administration services. The CY 2027 proposed rule would extend that approach to another significant outpatient service category, suggesting that CMS continues to view site-neutral payment as an important tool for reducing spending and beneficiary cost-sharing where it believes payment differentials are driven primarily by site of service rather than differences in care.

Implications for off-campus departments

CMS proposes to add a new defined term "off-campus outpatient department of a provider" at 42 C.F.R. § 413.65(a)(2), codifying the statutory definition Congress established in Section 6225 of the Consolidated Appropriations Act, 2026. Under the proposed definition, an off-campus outpatient department of a provider is a department "not located on the campus of the main provider or within 250 yards of a remote location of a hospital."

This is a new regulatory definition, not a revision to a prior defined term. CMS also proposes conforming changes to the existing off-campus provider-based requirements at § 413.65(e) to align those provisions with the statutory framework. Because the scope of the attestation and separate NPI requirements described below turns on which departments qualify under this new definition, health systems should assess whether their existing or planned departments fall within or outside its parameters.

Beginning January 1, 2028, no OPPS payment may be made for services furnished by an off-campus PBD unless that department bills under its own distinct national provider identifier (NPI). This is an enrollment and operational requirement, not a billing technicality. Health systems with large or dispersed outpatient footprints should begin NPI enrollment and systems reconfiguration now.

Notably, the separate NPI requirement appears to apply to off-campus departments regardless of facility fee eligibility. Freestanding emergency departments (EDs) remain excluded from billing a facility fee, but they are not necessarily exempt from the NPI requirement. Counsel should evaluate each freestanding ED's circumstances under the proposed definition and Section 6225 framework.

Finally, Section 6225 makes provider-based attestation mandatory, effective January 1, 2028, as a condition of OPPS payment. With the final rule expected later this year, hospitals have a narrow window to ensure attestations are submitted and accurate for every off-campus PBD. Non-compliance means loss of OPPS payment eligibility; an inaccurate attestation risks retroactive liability for prior periods. To that end, health systems should immediately inventory all off-campus PBDs and confirm each satisfies current provider-based standards, identify departments with missing or outdated attestations and coordinate with their Medicare Administrative Contractor on submission timing and process.

Conclusion

The CY 2027 proposed rule advances two long-standing CMS objectives: reducing 340B-related payment differentials and expanding site-neutral reimbursement. It also adds significant new compliance obligations for off-campus departments that require immediate attention regardless of how the final rule takes shape. If finalized, the rule will redistribute billions in OPPS payments and require health systems to satisfy attestation and NPI enrollment requirements well before January 1, 2028. Hospitals should assess the financial and operational impact now.

Comments on the proposed rule are due August 31, 2026. We encourage clients and other interested parties to consider submitting formal comments. This rulemaking presents a genuine opportunity to influence CMS's final determinations, and a well-documented comment supported by facility-specific operational or financial data can meaningfully shape both the substance and the administrative record of the final policy. Our firm has experience developing and submitting comments on CMS proposed rules on behalf of hospital and health system clients and would welcome the opportunity to assist.

Contact